Qian Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qian Liu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Lanying Du
Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
6 shared publications - Shengnan Qian
Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
4 shared publications - Xiaoqing Guan
Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
3 shared publications - Abhishek Kumar Verma
Department of Microbiology and Immunology, University of Iowa, Iowa City, IA 52242, USA
2 shared publications - Hansam Cho
Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
2 shared publications - Stanley Perlman
Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA
2 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10225
Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection
Severe acute respiratory syndrome 2 (SARS-CoV-2), the single-stranded RNA virus responsible for Coronavirus Disease 2019 (COVID-19), continues to circulate globally, with the emergence of antigenically distinct variants posing ongoing challenges to vaccine effectiveness. In particular, Omicron subvariants harbor numerous mutations in the receptor-binding domain (RBD), which contribute to immune evasion and reduced susceptibility to neutralization by antibodies. Previous COVID-19 mRNA vaccines encoding the spike (S) protein of the ancestral SARS-CoV-2 or early variants of concern have demonstrated limited efficacy against Omicron subvariants, underscoring the need for next-generation vaccines capable of eliciting broad-spectrum neutralizing antibodies against Omicron and providing cross-protection against antigenically distinct variants. In this study, we designed an mRNA vaccine encoding a conserved Omicron-S backbone incorporating the JN.1 RBD (S-JN1-RBD), formulated the mRNA with lipid nanoparticles (LNPs), and evaluated its neutralizing activity and protective efficacy. This mRNA-LNP formulation exhibited an appropriate particle size and high thermal stability. It elicited cross-reactive antibodies against S proteins harboring diverse Omicron-RBDs, resulting in broad neutralizing activity against multiple pseudotyped and authentic SARS-CoV-2 Omicron subvariants. Importantly, this vaccine conferred cross-protection against challenge with the heterologous, antigenically divergent XBB.1.5 Omicron subvariant in human angiotensin-converting enzyme 2-transgenic mice. Furthermore, passive transfer of immune sera protected mice against infection with the Omicron-KP.3 subvariant, providing additional evidence of the vaccine’s broad protective potential. These findings underscore the potential of the designed mRNA immunogen to elicit broad-spectrum neutralizing antibody responses and to confer cross-protection against diverse and emerging SARS-CoV-2 subvariants.
- 15 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10225
Open AccessSpike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection
Severe acute respiratory syndrome 2 (SARS-CoV-2), the single-stranded RNA virus responsible for Coronavirus Disease 2019 (COVID-19), continues to circulate globally, with the emergence of antigenically distinct variants posing ongoing challenges to vaccine effectiveness. In particular, Omicron subvariants harbor numerous mutations in the receptor-binding domain (RBD), which contribute to immune evasion and reduced susceptibility to neutralization by antibodies. Previous COVID-19 mRNA vaccines encoding the spike (S) protein of the ancestral SARS-CoV-2 or early variants of concern have demonstrated limited efficacy against Omicron subvariants, underscoring the need for next-generation vaccines capable of eliciting broad-spectrum neutralizing antibodies against Omicron and providing cross-protection against antigenically distinct variants. In this study, we designed an mRNA vaccine encoding a conserved Omicron-S backbone incorporating the JN.1 RBD (S-JN1-RBD), formulated the mRNA with lipid nanoparticles (LNPs), and evaluated its neutralizing activity and protective efficacy. This mRNA-LNP formulation exhibited an appropriate particle size and high thermal stability. It elicited cross-reactive antibodies against S proteins harboring diverse Omicron-RBDs, resulting in broad neutralizing activity against multiple pseudotyped and authentic SARS-CoV-2 Omicron subvariants. Importantly, this vaccine conferred cross-protection against challenge with the heterologous, antigenically divergent XBB.1.5 Omicron subvariant in human angiotensin-converting enzyme 2-transgenic mice. Furthermore, passive transfer of immune sera protected mice against infection with the Omicron-KP.3 subvariant, providing additional evidence of the vaccine’s broad protective potential. These findings underscore the potential of the designed mRNA immunogen to elicit broad-spectrum neutralizing antibody responses and to confer cross-protection against diverse and emerging SARS-CoV-2 subvariants.
- Open Access
- 9 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4218
Immunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant
The surface spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key target for the development of Coronavirus Disease 2019 (COVID-19) vaccines. Nevertheless, the mutations in the S protein, particularly in its receptor-binding domain region, have resulted in a reduced or complete loss of immunogenicity and/or protective efficacy in early vaccines against the Omicron variant and subvariants. Accordingly, continuous efforts are required to develop effective vaccines against multiple Omicron subvariants to reduce current and future threats. In this study, we designed an mRNA vaccine targeting the S protein of a recent Omicron-XEC subvariant (XEC-S-mRNA) and assessed its immunogenicity, including its broad neutralizing activity, and its protective efficacy against multiple Omicron subvariants. Our results demonstrated that the lipid nanoparticle-formulated mRNA vaccine formed an appropriate particle size with strong stability and successful antigen expression. It elicited durable cellular immune responses and broad neutralizing antibodies against multiple early and recent Omicron subvariants, thereby cross-protecting transgenic mice from challenge with a heterologous Omicron strain (KP.3). Moreover, the vaccine-induced neutralizing antibodies alone were sufficient to prevent Omicron-KP.3 infection. Overall, this study shows promise for further development of the candidate vaccine against current and future Omicron infections.
- 9 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4218
Open AccessImmunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant
The surface spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key target for the development of Coronavirus Disease 2019 (COVID-19) vaccines. Nevertheless, the mutations in the S protein, particularly in its receptor-binding domain region, have resulted in a reduced or complete loss of immunogenicity and/or protective efficacy in early vaccines against the Omicron variant and subvariants. Accordingly, continuous efforts are required to develop effective vaccines against multiple Omicron subvariants to reduce current and future threats. In this study, we designed an mRNA vaccine targeting the S protein of a recent Omicron-XEC subvariant (XEC-S-mRNA) and assessed its immunogenicity, including its broad neutralizing activity, and its protective efficacy against multiple Omicron subvariants. Our results demonstrated that the lipid nanoparticle-formulated mRNA vaccine formed an appropriate particle size with strong stability and successful antigen expression. It elicited durable cellular immune responses and broad neutralizing antibodies against multiple early and recent Omicron subvariants, thereby cross-protecting transgenic mice from challenge with a heterologous Omicron strain (KP.3). Moreover, the vaccine-induced neutralizing antibodies alone were sufficient to prevent Omicron-KP.3 infection. Overall, this study shows promise for further development of the candidate vaccine against current and future Omicron infections.
- Open Access
Omicron KP.3 RBD-Containing Spike mRNA Vaccine Induces Broadly Neutralizing Antibodies with Protection Against SARS-CoV-2 Omicron Infection in Mice
Background/Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the global COVID-19 pandemic, which led to hundreds of millions of human infections and more than seven million deaths worldwide. Major variants of concern, particularly the Omicron variant and its associated subvariants, can escape the vaccines developed so far to target previous strains/subvariants. Therefore, effective vaccines that broadly neutralize different Omicron subvariants and show good protective efficacy are needed to prevent further spread of Omicron. The spike (S) protein, including its receptor-binding domain (RBD), is a key vaccine target. Methods: Here, we designed a unique mRNA vaccine encoding Omicron-KP.3 RBD based on RBD-truncated S protein backbone of an earlier Omicron subvariant EG.5 (KP3 mRNA), and evaluated its stability, immunogenicity, neutralizing activity, and protective efficacy in a mouse model. Results: Our data showed that the nucleoside-modified, lipid nanoparticle-encapsulated mRNA vaccine was stable at various temperatures during the period of detection. In addition, the vaccine elicited potent antibody responses with broadly neutralizing activity against multiple Omicron subvariants, including KP.2, KP.3, XEC, and NB.1.8.1. This mRNA vaccine protected immunized transgenic mice from challenge with SARS-CoV-2 Omicron-KP.3. Immune serum also protected against subsequent virus challenge, with the level of protection associating positively with the serum neutralizing antibody titer. Conclusions: Taken together, the data presented herein suggest that this newly designed mRNA vaccine has potential against current and future Omicron subvariants.
Open AccessOmicron KP.3 RBD-Containing Spike mRNA Vaccine Induces Broadly Neutralizing Antibodies with Protection Against SARS-CoV-2 Omicron Infection in Mice
Background/Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the global COVID-19 pandemic, which led to hundreds of millions of human infections and more than seven million deaths worldwide. Major variants of concern, particularly the Omicron variant and its associated subvariants, can escape the vaccines developed so far to target previous strains/subvariants. Therefore, effective vaccines that broadly neutralize different Omicron subvariants and show good protective efficacy are needed to prevent further spread of Omicron. The spike (S) protein, including its receptor-binding domain (RBD), is a key vaccine target. Methods: Here, we designed a unique mRNA vaccine encoding Omicron-KP.3 RBD based on RBD-truncated S protein backbone of an earlier Omicron subvariant EG.5 (KP3 mRNA), and evaluated its stability, immunogenicity, neutralizing activity, and protective efficacy in a mouse model. Results: Our data showed that the nucleoside-modified, lipid nanoparticle-encapsulated mRNA vaccine was stable at various temperatures during the period of detection. In addition, the vaccine elicited potent antibody responses with broadly neutralizing activity against multiple Omicron subvariants, including KP.2, KP.3, XEC, and NB.1.8.1. This mRNA vaccine protected immunized transgenic mice from challenge with SARS-CoV-2 Omicron-KP.3. Immune serum also protected against subsequent virus challenge, with the level of protection associating positively with the serum neutralizing antibody titer. Conclusions: Taken together, the data presented herein suggest that this newly designed mRNA vaccine has potential against current and future Omicron subvariants.
- Open Access
MERS-CoV RBD-mRNA Presents Better Immunogenicity and Protection than the Spike-mRNA
Pathogenic Middle East respiratory syndrome CoV (MERS-CoV), first identified in Saudi Arabia in 2012, continues to pose a threat to public health. The trimeric spike (S) protein of MERS-CoV binds to the cellular receptor through the receptor-binding domain (RBD) in the S1 subunit to initiate virus entry and infection. Therefore, both the S protein and its RBD are targets for the development of MERS-CoV vaccines. Nevertheless, a direct comparison of the immune efficiency of S- and RBD-based MERS-CoV vaccines has not been made. Here, we compared two mRNA vaccines, respectively, targeting the S (S-mRNA) and RBD (RBD-mRNA) of MERS-CoV for their durable immunogenicity, neutralizing activity, and protective efficacy in a mouse model. Both mRNAs encapsulated with lipid nanoparticles (LNPs) maintained strong stability at various temperatures during the detection period. LNP-encapsulated RBD-mRNA elicited significantly higher and more durable antibodies than LNP-encapsulated S-mRNA, maintaining stronger and broadly neutralizing activity against the MERS-CoV original strain, as well as multiple variants containing key mutations within the RBD region. Importantly, RBD-mRNA provided durable protective efficacy against MERS-CoV infection in middle-aged mice, and this protection was associated positively with serum neutralizing antibody titers. Overall, this study identifies RBD-mRNA as an effective vaccine against MERS-CoV, with great potential for further development.
Open AccessMERS-CoV RBD-mRNA Presents Better Immunogenicity and Protection than the Spike-mRNA
Pathogenic Middle East respiratory syndrome CoV (MERS-CoV), first identified in Saudi Arabia in 2012, continues to pose a threat to public health. The trimeric spike (S) protein of MERS-CoV binds to the cellular receptor through the receptor-binding domain (RBD) in the S1 subunit to initiate virus entry and infection. Therefore, both the S protein and its RBD are targets for the development of MERS-CoV vaccines. Nevertheless, a direct comparison of the immune efficiency of S- and RBD-based MERS-CoV vaccines has not been made. Here, we compared two mRNA vaccines, respectively, targeting the S (S-mRNA) and RBD (RBD-mRNA) of MERS-CoV for their durable immunogenicity, neutralizing activity, and protective efficacy in a mouse model. Both mRNAs encapsulated with lipid nanoparticles (LNPs) maintained strong stability at various temperatures during the detection period. LNP-encapsulated RBD-mRNA elicited significantly higher and more durable antibodies than LNP-encapsulated S-mRNA, maintaining stronger and broadly neutralizing activity against the MERS-CoV original strain, as well as multiple variants containing key mutations within the RBD region. Importantly, RBD-mRNA provided durable protective efficacy against MERS-CoV infection in middle-aged mice, and this protection was associated positively with serum neutralizing antibody titers. Overall, this study identifies RBD-mRNA as an effective vaccine against MERS-CoV, with great potential for further development.
- Open Access
Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoV
Background. The pathogenic coronaviruses (CoVs) MERS-CoV and SARS-CoV-2, which are responsible for the MERS outbreak and the COVID-19 pandemic, respectively, continue to infect humans, with significant adverse outcomes. There is a continuing need to develop mucosal vaccines against these respiratory viral pathogens to prevent entry and replication at mucosal sites. The receptor-binding domain (RBD) of the CoV spike (S) protein is a critical vaccine target, and glycan masking is a unique approach for designing subunit vaccines with improved neutralizing activity. Methods. We evaluated the efficacy of mucosal immunity, broad neutralizing activity, and cross-protection afforded by a combined glycosylated mucosal subunit vaccine encoding the RBDs of the original SARS-CoV-2 strain (SARS2-WT-RBD), the Omicron-XBB.1.5 variant (SARS2-Omi-RBD), and MERS-CoV (MERS-RBD). Results. Intranasal administration of the three-RBD protein cocktail induced effective, durable IgA and systemic IgG antibodies specific for the S protein of these CoVs, thereby neutralizing infection by pseudotyped SARS-CoV-2-WT, Omicron-XBB.1.5, and MERS-CoV. The mucosal vaccine cocktail protected immunized mice from challenge with SARS-CoV-2 Omicron-XBB.1.5 and MERS-CoV, leading to a significant reduction in the viral titers in the lungs. By contrast, the individual glycosylated RBD proteins only induced such immune responses and neutralizing antibodies against either SARS-CoV-2 or MERS-CoV, protecting against subsequent challenge with either SARS-CoV-2 or MERS-CoV; they did not provide simultaneous protection against both CoVs. Conclusions. This study describes a unique strategy for designing efficacious mucosal subunit vaccines that induce durable mucosal immunity, cross-neutralizing activity, and cross-protection against SARS-CoV-2 and MERS-CoV, highlighting the potential for the design of mucosal vaccines against other pathogens.
Open AccessGlycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoV
Background. The pathogenic coronaviruses (CoVs) MERS-CoV and SARS-CoV-2, which are responsible for the MERS outbreak and the COVID-19 pandemic, respectively, continue to infect humans, with significant adverse outcomes. There is a continuing need to develop mucosal vaccines against these respiratory viral pathogens to prevent entry and replication at mucosal sites. The receptor-binding domain (RBD) of the CoV spike (S) protein is a critical vaccine target, and glycan masking is a unique approach for designing subunit vaccines with improved neutralizing activity. Methods. We evaluated the efficacy of mucosal immunity, broad neutralizing activity, and cross-protection afforded by a combined glycosylated mucosal subunit vaccine encoding the RBDs of the original SARS-CoV-2 strain (SARS2-WT-RBD), the Omicron-XBB.1.5 variant (SARS2-Omi-RBD), and MERS-CoV (MERS-RBD). Results. Intranasal administration of the three-RBD protein cocktail induced effective, durable IgA and systemic IgG antibodies specific for the S protein of these CoVs, thereby neutralizing infection by pseudotyped SARS-CoV-2-WT, Omicron-XBB.1.5, and MERS-CoV. The mucosal vaccine cocktail protected immunized mice from challenge with SARS-CoV-2 Omicron-XBB.1.5 and MERS-CoV, leading to a significant reduction in the viral titers in the lungs. By contrast, the individual glycosylated RBD proteins only induced such immune responses and neutralizing antibodies against either SARS-CoV-2 or MERS-CoV, protecting against subsequent challenge with either SARS-CoV-2 or MERS-CoV; they did not provide simultaneous protection against both CoVs. Conclusions. This study describes a unique strategy for designing efficacious mucosal subunit vaccines that induce durable mucosal immunity, cross-neutralizing activity, and cross-protection against SARS-CoV-2 and MERS-CoV, highlighting the potential for the design of mucosal vaccines against other pathogens.
- Open Access
- 30 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9424
Envelope Protein-Targeting Zika Virus Entry Inhibitors
Zika virus (ZIKV; family, Flaviviridae), which causes congenital Zika syndrome, Guillain-Barré Syndrome, and other severe diseases, is transmitted mainly by mosquitoes; however, the virus can be transmitted through other routes. Among the three structural and seven nonstructural proteins, the surface envelope (E) protein of ZIKV plays a critical role in viral entry and pathogenesis, making it a key target for the development of effective entry inhibitors. This review article describes the life cycle, genome, and encoded proteins of ZIKV, illustrates the structure and function of the ZIKV E protein, summarizes E protein-targeting entry inhibitors (with a focus on those based on natural products and small molecules), and highlights challenges that may potentially hinder the development of effective inhibitors of ZIKV infection. Overall, the article will provide useful guidance for further development of safe and potent ZIKV entry inhibitors targeting the viral E protein.
- 30 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9424
Open AccessEnvelope Protein-Targeting Zika Virus Entry Inhibitors
Zika virus (ZIKV; family, Flaviviridae), which causes congenital Zika syndrome, Guillain-Barré Syndrome, and other severe diseases, is transmitted mainly by mosquitoes; however, the virus can be transmitted through other routes. Among the three structural and seven nonstructural proteins, the surface envelope (E) protein of ZIKV plays a critical role in viral entry and pathogenesis, making it a key target for the development of effective entry inhibitors. This review article describes the life cycle, genome, and encoded proteins of ZIKV, illustrates the structure and function of the ZIKV E protein, summarizes E protein-targeting entry inhibitors (with a focus on those based on natural products and small molecules), and highlights challenges that may potentially hinder the development of effective inhibitors of ZIKV infection. Overall, the article will provide useful guidance for further development of safe and potent ZIKV entry inhibitors targeting the viral E protein.
- Open Access
- 5 May 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (19)
CRISPR-Cas9 editing of the arginine–vasopressin V1a receptor produces paradoxical changes in social behavior in Syrian hamsters
Significance: Arginine–vasopressin (AVP) acting on V1a receptors (Avpr1as) represents a key signaling mechanism in a brain circuit that increases the expression of social communication and aggression. We produced Syrian hamsters that completely lack Avpr1as (Avpr1aknockout [KO] hamsters) using the CRISPR-Cas9 system to more fully examine the role of Avpr1a in the expression of social behaviors. We confirmed the absence of Avpr1as in these hamsters by demonstrating 1) a complete lack of Avpr1a-specific receptor binding throughout the brain, 2) a behavioral insensitivity to centrally administered AVP, and 3) an absence of the well-known blood-pressure response produced by activating Avpr1as. Unexpectedly, however,Avpr1aKO hamsters displayed more social communication behavior and aggression toward same-sex conspecifics than did their wild-type (WT) littermates.
- 5 May 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (19)
Open AccessCRISPR-Cas9 editing of the arginine–vasopressin V1a receptor produces paradoxical changes in social behavior in Syrian hamsters
Significance: Arginine–vasopressin (AVP) acting on V1a receptors (Avpr1as) represents a key signaling mechanism in a brain circuit that increases the expression of social communication and aggression. We produced Syrian hamsters that completely lack Avpr1as (Avpr1aknockout [KO] hamsters) using the CRISPR-Cas9 system to more fully examine the role of Avpr1a in the expression of social behaviors. We confirmed the absence of Avpr1as in these hamsters by demonstrating 1) a complete lack of Avpr1a-specific receptor binding throughout the brain, 2) a behavioral insensitivity to centrally administered AVP, and 3) an absence of the well-known blood-pressure response produced by activating Avpr1as. Unexpectedly, however,Avpr1aKO hamsters displayed more social communication behavior and aggression toward same-sex conspecifics than did their wild-type (WT) littermates.